You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Appropriate Use of Glucocorticoids in the Treatment of SLE

  • Authors: Eric Morand, MD; Ronald van Vollenhoven, MD, PhD
  • CPD Released: 6/24/2021
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 6/24/2022, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US rheumatologists, nephrologists, nurses, and primary care physicians.

The goal of this activity is to review the benefits of glucocorticoid (GC) therapy in systemic lupus erythematosus (SLE) and to highlight strategies to minimize long-term or high-dose GC use to reduce the risk of organ damage accrual.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Impact of inappropriate GC treatment in SLE
    • Strategies to minimize the long-term use of GCs in SLE
  • Have greater competence related to the
    • Appropriate use of GC therapy for the treatment of SLE


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Eric Morand, MD

    Professor
    Head
    School of Clinical Sciences at Monash Health
    Monash University
    Melbourne, Australia

    Disclosures

    Disclosure: Eric Morand, MD, has the following relevant financial relationships:
    Advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biogen; Bristol Myers Squibb Company; Eli Lilly and Company; Genentech, Inc; GlaxoSmithKline; Janssen Pharmaceuticals; Wolf Biotherapeutics
    Speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company
    Grants for clinical research from: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; EMD Serono, Inc; GlaxoSmithKline; Janssen Pharmaceuticals

  • Ronald van Vollenhoven, MD, PhD

    Professor
    Amsterdam University Medical Center
    Amsterdam, The Netherlands

    Disclosures

    Disclosure: Ronald van Vollenhoven, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: AbbVie, Inc; AstraZeneca Pharmaceuticals LP; Biogen; Biotest; Celgene Corporation; Galapagos; Gilead Sciences, Inc; Janssen Pharmaceuticals; Pfizer, Inc; Sanofi; Servier; UCB Pharma, Inc; Vielabo
    Speaker or a member of a speakers bureau for: AbbVie, Inc; Galapagos; GlaxoSmithKline; Janssen Pharmaceuticals; Pfizer, Inc; UCB Pharma, Inc
    Grants for clinical research from: Bristol Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; UCB Pharma, Inc

Editors

  • Marinella Calle, PhD, CMPP

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Marinella Calle, PhD, CMPP, has disclosed no relevant financial relationships.

  • Diana Lucifero, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Diana Lucifero, PhD, has disclosed no relevant financial relationships.

Content Reviewer

  • Esther Nyarko, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Appropriate Use of Glucocorticoids in the Treatment of SLE

Authors: Eric Morand, MD; Ronald van Vollenhoven, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 6/24/2021

Valid for credit through: 6/24/2022, 11:59 PM EST

processing....

 
 
 
 

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, manufacturer names related to the approved COVID-19 vaccines are provided in this activity in an effort to promote clarity. The use of manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.

Educational Impact Challenge

The goal of this activity is to review the benefits of glucocorticoid (GC) therapy in systemic lupus erythematosus (SLE) and to highlight strategies to minimize long-term or high-dose GC use to reduce the risk of organ damage accrual.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print